Picture of RTW Biotech Opportunities logo

RTWG — RTW Biotech Opportunities News Story

0.000.00%
gb flag iconLast trade - 00:00
FinancialsBalancedMid CapNeutral

Publication of Circular & Convening of EGM

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA1152Ia&default-theme=true

RNS Number : 1152I  RTW Venture Fund Limited  01 December 2022

LEI: 549300Q7EXQQH6KF7Z84

1 December 2022

RTW Venture Fund Limited

Publication of Circular & Convening of EGM

Further to the announcement on 28 November 2022, RTW Venture Fund Limited (the
"Company") announces that documentation has been filed with the U.S. Internal
Revenue Service to change the Company's tax status, with effect from 1
December 2022, from a "publicly traded partnership" or "PTP" to a corporation
for U.S. federal tax purposes ("Tax Election").

A shareholder circular (the "Circular") has been published today on the
Company's website at www.rtwfunds.com/venture-fund
(http://www.rtwfunds.com/venture-fund) . In addition,  a copy of the Circular
has been submitted to the National Storage Mechanism and will shortly be
available for viewing online at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

A notice of an Extraordinary General Meeting ("EGM") is contained in the
Circular. At the EGM, Shareholders will be asked (a) to approve the adoption
of new articles of incorporation, which will be updated to reflect the U.S.
federal tax status of the Company following completion of the Tax Election and
the reorganisation; and (b) to ratify the decision of the Board to make the
Tax Election.

This information is not intended to be all-inclusive or to render specific
professional tax advice.  Shareholders are urged to consult with their
independent tax advisors to determine the tax consequences. The Company does
not provide tax or legal advice.

For Further Information:

 RTW Investments, LP                               +44 (0) 77 1741 7711
 Woody Stileman, Managing Director

 Buchanan                                          +44 (0)20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 J.P. Morgan Cazenove                              +44 (0)20 7742 4000
 William Simmonds
 Jérémie Birnbaum
 James Bouverat (Sales)

 BofA Securities                                   +44 (0) 20 7628 1000
 Edward Peel
 Kieran Millar

 Elysium Fund Management Limited                   +44 (0) 14 8181 0100
 Joanna Duquemin Nicolle, Chief Executive Officer
 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC              +1 (914) 225 8885

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused
on identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Venture Fund invests in
companies developing next-generation therapies and technologies that can
significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading
healthcare-focused entrepreneurial investment firm with deep scientific
expertise and a strong track record of supporting companies developing
life-changing therapies.

Visit the RTW website at www.rtwfunds.com
(https://protect-us.mimecast.com/s/_A8aC5y408fDJXqhzbVHJ?domain=protect.mimecast-offshore.com)
for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFDDFDSEESEDF

Recent news on RTW Biotech Opportunities

See all news